Rani Therapeutics Holdings (RANI) Non-Current Debt (2020 - 2025)

Rani Therapeutics Holdings' Non-Current Debt history runs 5 years deep, the most recent figure standing at $2.2 million for Q2 2025.

• On a quarterly basis, Non-Current Debt fell 87.05% year-over-year to $2.2 million in Q2 2025; TTM through Jun 2025 was $2.2 million, a 87.05% decrease from a year earlier, with the FY2024 full-year figure at $9.6 million, down 60.74% from the prior year.
• Non-Current Debt slipped to $2.2 million in Q2 2025 per RANI's latest filing, from $5.9 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $29.3 million in Q2 2023 and bottomed at $2.2 million in Q2 2025.
• The 4-year median for Non-Current Debt is $19.0 million (2024), against an average of $18.6 million.
• Across the five-year window, Non-Current Debt soared 99.43% in 2023 and sank 87.05% in 2025, its largest moves.
• Year by year, Non-Current Debt stood at $29.1 million in 2022, then slipped by 16.0% to $24.5 million in 2023, then plunged by 60.74% to $9.6 million in 2024, then tumbled by 76.81% to $2.2 million in 2025.
• Per Business Quant, the three latest RANI Non-Current Debt figures stand at $2.2 million (Q2 2025), $5.9 million (Q1 2025), and $9.6 million (Q4 2024).